Modelling in the Quantitative Analysis of Brain PET Scans in Patients With Alzheimer's Disease

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

25 participants

Study Classification

OBSERVATIONAL

Study Start Date

2021-02-01

Study Completion Date

2022-02-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

PET/CT scans with 18F-FDG can be carried out for the detection of neurodegenerative diseases with hypometabolisms characteristic of the pathologies sought. The diagnosis is given by the clinician after a visual analysis of the data. To complete the diagnosis, a semi-quantitative analysis of the images is recommended (European recommendations) in addition to the visual analysis.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Risk of Developing Dementia and Associated Factors in Patients With Normal Brain FDG PET

NCT04804722

Neurodegenerative Diseases Cognitive Disorder

COMPLETED

Study of the Indications for Amyloid Positon Emission Tomography (PET) Scans and Their Usefulness for Patients With Suspected Alzheimer's Disease (AD)

NCT06467981

Alzheimer Disease

COMPLETED

Positron Emission Tomography of Amyloid in Alzheimer's Disease

NCT00205621

Alzheimer's Disease

SUSPENDED PHASE1

18F-Florbetaben PET Amyloid Imaging in Case of Intermediate CSF Biology for the Diagnosis of Alzheimer's Disease : a Pilot Study

NCT02556502

Amyloid PET Imaging

COMPLETED NA

Database of Positon Emission Tomography (PET) Digital Brain Exams, in 50th Age of Patients

NCT04163276

Neurodegenerative Diseases

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

PET/CT scans with 18F-FDG can be carried out for the detection of neurodegenerative diseases with hypometabolisms characteristic of the pathologies sought. The diagnosis is given by the clinician after a visual analysis of the data. To complete the diagnosis, a semi-quantitative analysis of the images is recommended (European recommendations) in addition to the visual analysis.

PET technology is improving from year to year thanks to the arrival of a new PET technology called digital. In addition, correction methods have been developed to improve PET images and thus improve the detection of different pathologies in PET.

The PSF (Point Spread Function) tool enables partial volume effects to be corrected. The PSF consists of correcting the impulse response of the system, and allows a visual improvement of the images. Currently not recommended in brain PET/CT reconstructions, it remains to be evaluated for the quantitative analysis of acquisitions.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Patients With Alzheimer's Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Patient with Alzheimer disease

Patients recruited retrospectively with the available nuclear medicine listing of patients who performed brain PET/CT scans in the nuclear medicine department from December 2017 to December 2020.

Brain positron emission tomopgraphy (PET) - scan

Intervention Type DEVICE

Patients who performed brain PET/CT scans in the nuclear medicine department from December 2017 to December 2020.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Brain positron emission tomopgraphy (PET) - scan

Patients who performed brain PET/CT scans in the nuclear medicine department from December 2017 to December 2020.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Brain PET/CT scans at 18F-FDG of patients with Alzheimer's disease carried out in the nuclear medicine department of the Nancy-Brabois University Hospital since December 2017 on digital PET devices.